Human VEGF R1/Flt-1 Quantikine ELISA Kit

  (45 citations)   
Product Details
Citations (45)
FAQs
Supplemental Products
Reviews
  • Assay Length
    4.5 hours
  • Sample Type & Volume Required Per Well
    Cell Culture Supernates (100 uL), Cell Lysates (10 uL), Serum (100 uL), EDTA Plasma (100 uL), Heparin Plasma (100 uL), Saliva (100 uL)
  • Sensitivity
    8.46 pg/mL
  • Assay Range
    31.3 - 2,000 pg/mL (Cell Culture Supernates, Cell Lysates, Serum, EDTA Plasma, Heparin Plasma, Saliva)
  • Specificity
    Natural and recombinant human soluble VEGF R1
  • Cross-reactivity
    < 0.5% cross-reactivity observed with available related molecules.< 50% cross-species reactivity observed with species tested.
  • Interference
    No significant interference observed with available related molecules.
Control Available
QC239 , Quantikine Immunoassay Control Set 935 for Human VEGF R1 - Please Inquire
Product Summary
The Quantikine Human VEGF R1 Immunoassay is a 4.5 hour solid-phase ELISA designed to measure human soluble VEGF R1 in cell culture supernates, serum, plasma, saliva, and follicular fluid. It contains Sf 21-expressed recombinant human VEGF R1/Fc Chimera and has been shown to accurately quantitate the recombinant factor. Results obtained using natural human VEGF R1 showed linear curves that were parallel to the standard curves obtained using the Quantikine kit standards. These results indicate that this kit can be used to determine relative mass values for naturally occurring soluble VEGF R1.

Precision
Intra-Assay Precision (Precision within an assay) Three samples of known concentration were tested on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays) Three samples of known concentration were tested in separate assays to assess inter-assay precision.
Cell Culture Supernates, Serum, EDTA Plasma, Saliva, Follicular Fluid
Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 1 2 3
n 20 20 20 20 20 20
Mean 96.6 596 1213 112 645 1279
Standard Deviation 2.5 22.8 39.3 11 44.9 70.5
CV% 2.6 3.8 3.2 9.8 7 5.5

Cell Culture Supernates, Cell Lysates, Serum, EDTA Plasma, Heparin Plasma, Saliva
Intra-Assay Precision Inter-Assay Precision
Sample 1 2 3 1 2 3
n 20 20 20 20 20 20
Mean 207 610 1207 207 616 1205
Standard Deviation 5.16 14.9 35.6 13.9 38.9 74
CV% 2.5 2.4 2.9 6.7 6.3 6.1

Recovery

The recovery of VEGF R1 spiked to levels throughout the range of the assay in various matrices was evaluated.

Sample Type Average % Recovery Range %
Cell Culture Media (n=4) 99 87-110
Cell Lysis Buffer (n=4) 94 86-108
EDTA Plasma (n=4) 92 84-98
Heparin Plasma (n=4) 89 81-96
Saliva (n=4) 109 96-124
Serum (n=4) 104 93-114
Linearity
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of VEGF R1 were serially diluted with Calibrator Diluent to produce samples with values within the dynamic range of the assay.
Human VEGF R1/Flt-1 Quantikine ELISA Kit
Preparation and Storage
  • Storage
    Store the unopened product at 2 - 8 °C. Do not use past expiration date.
Background: VEGF R1/Flt-1

VEGF R1 (Flt-1), VEGF R2 (KDR/Flk-1), and VEGF R3 (Flt-4) belong to the class III subfamily of receptor tyrosine kinases (RTKs). All three receptors contain seven immunoglobulin-like repeats in their extracellular domain and kinase insert domains in their intracellular region. They are best known for regulating VEGF family-mediated vasculogenesis, angiogenesis, and lymphangiogenesis. They are also mediators of neurotrophic activity and regulators of hematopoietic development. VEGF R2 is thought to be the primary inducer of VEGF-mediated blood vessel growth, while VEGF R3 plays a significant role in VEGF-C and VEGF-D-mediated lymphangiogenesis.

  • Long Name:
    Vascular Endothelial Growth Factor Receptor 1
  • Entrez Gene IDs:
    2321 (Human); 14254 (Mouse)
  • Alternate Names:
    EC 2.7.10; EC 2.7.10.1; FLT; FLT1; Flt-1; Fms-like tyrosine kinase 1; fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascularpermeability factor receptor); FRT; Tyrosine-protein kinase FRT; Tyrosine-protein kinase receptor FLT; vascular endothelial growth factor receptor 1; Vascular permeability factor receptor; VEGF R1; VEGFR1; VEGFR-1
Related Research Areas
Citations:

R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.

45 Citations: Showing 1 - 10
Filter your results:

Species
Sample Type
  1. Endothelial Dysfunction in Severe Preeclampsia is Mediated by Soluble Factors, Rather than Extracellular Vesicles
    Authors: M O'Brien, D Baczyk, JC Kingdom
    Sci Rep, 2017;7(1):5887.
    Species: Human
    Sample Type: Tissue Culture Supernates
  2. Albuminuria Is Associated with Endothelial Dysfunction and Elevated Plasma Endothelin-1 in Sickle Cell Anemia
    PLoS ONE, 2016;11(9):e0162652.
    Species: Human
    Sample Type: Plasma
  3. Association between Placental Lesions, Cytokines and Angiogenic Factors in Pregnant Women with Preeclampsia
    Authors: Ingrid C Weel
    PLoS ONE, 2016;11(6):e0157584.
    Species: Human
    Sample Type: Tissue Homogenates
  4. Inhibition of placental growth factor in renal cell carcinoma.
    Authors: Bessho H, Wong B, Huang D, Siew E, Huang D, Tan J, Ong C, Tan S, Matsumoto K, Iwamura M, Teh B
    Anticancer Res, 2015;35(1):531-41.
    Species: Human
    Sample Type: Cell Culture Supernates
  5. Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer.
    Authors: Sallinen H, Heikura T, Koponen J, Kosma V, Heinonen S, Yla-Herttuala S, Anttila M
    BMC Cancer, 2014;14(0):696.
    Species: Human
    Sample Type: Serum
  6. FLT1 genetic variation predisposes to neovascular AMD in ethnically diverse populations and alters systemic FLT1 expression.
    Authors: Owen, Leah A, Morrison, Margaux, Ahn, Jeeyun, Woo, Se Joon, Sato, Hajime, Robinson, Rosann, Morgan, Denise J, Zacharaki, Fani, Simeonova, Marina, Uehara, Hironori, Chakravarthy, Usha, Hogg, Ruth E, Ambati, Balamura, Kotoula, Maria, Baehr, Wolfgang, Haider, Neena B, Silvestri, Giuliana, Miller, Joan W, Tsironi, Evangeli, Farrer, Lindsay, Kim, Ivana K, Park, Kyu Hyun, DeAngelis, Margaret
    Invest Ophthalmol Vis Sci, 2014;55(6):3543-54.
    Species: Human
    Sample Type: Serum
  7. Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy.
    Authors: Necchi A, Pennati M, Zaffaroni N, Landoni E, Giannatempo P, Raggi D, Schwartz L, Morosi C, Crippa F, Fare E, Nicolai N, Lanocita R, Sava T, Sacco C, Messina C, Ortega C, De Braud F, Salvioni R, Daidone M, Gianni A, Mariani L
    Br J Cancer, 2014;110(1):26-33.
    Species: Human
    Sample Type: Plasma
  8. Placental growth factor and soluble Fms-like tyrosine kinase 1 in diabetic pregnancy: A possible relation to distal villous immaturity.
    Authors: El-Tarhouny S, Almasry S, Elfayomy A, Baghdadi H, Habib F
    Histol Histopathol, 2014;29(2):259-72.
    Species: Human
    Sample Type: Serum
  9. Persistent urinary podocyte loss following preeclampsia may reflect subclinical renal injury.
    Authors: White W, Garrett A, Craici I, Wagner S, Fitz-Gibbon P, Butters K, Brost B, Rose C, Grande J, Garovic V
    PLoS ONE, 2014;9(3):e92693.
    Species: Human
    Sample Type: Serum
  10. Advanced oxidation protein products enhances soluble Fms-like tyrosine kinase 1 expression in trophoblasts: a possible link between oxidative stress and preeclampsia.
    Authors: Huang Q, Wang S, Zhang M, Huang L, Tian J, Yu Y, Wang Z, Zhong M
    Placenta, 2013;34(10):949-52.
    Species: Human
    Sample Type: Cell Culture Supernates
  11. Role of serum concentration of VEGFR1 and TIMP2 on clinical outcome in primary cervical cancer: results of a companion protocol of the randomized, NOGGO-AGO phase III adjuvant trial of simultaneous cisplatin-based radiochemotherapy vs. carboplatin and paclitaxel containing sequential radiotherapy.
    Authors: Braicu E, Fotopoulou C, Chekerov R, Richter R, Blohmer J, Kummel S, Stamatian F, Yalcinkaya I, Mentze M, Lichtenegger W, Sehouli J
    Cytokine, 2013;61(3):755-8.
    Species: Human
    Sample Type: Serum
  12. Integrating multiple 'omics' analyses identifies serological protein biomarkers for preeclampsia.
    Authors: Liu, Linda Y, Yang, Ting, Ji, Jun, Wen, Qiaojun, Morgan, Alexande, Jin, Bo, Chen, Gongxing, Lyell, Deirdre, Stevenson, David K, Ling, Xuefeng, Butte, Atul J
    BMC Med, 2013;11(0):236.
    Species: Human
    Sample Type: Serum
  13. A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment.
    Authors: Suzuki T, Shimada H, Makizako H, Doi T, Yoshida D, Ito K, Shimokata H, Washimi Y, Endo H, Kato T
    PLoS ONE, 2013;8(4):e61483.
    Species: Human
    Sample Type: Serum
  14. Fcgamma receptor-induced soluble vascular endothelial growth factor receptor-1 (VEGFR-1) production inhibits angiogenesis and enhances efficacy of anti-tumor antibodies.
    Authors: Justiniano S, Elavazhagan S, Fatehchand K, Shah P, Mehta P, Roda J, Mo X, Cheney C, Hertlein E, Eubank T, Marsh C, Muthusamy N, Butchar J, Byrd J, Tridandapani S
    J Biol Chem, 2013;288(37):26800-9.
    Species: Human
    Sample Type: Cell Culture Supernates
  15. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy.
    Authors: Patten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, Hacker MR, Rhee JS, Mitchell J, Mahmood F, Hess P, Farrell C, Koulisis N, Khankin EV, Burke SD, Tudorache I, Bauersachs J, del Monte F, Hilfiker-Kleiner D, Karumanchi SA, Arany Z
    Nature, 2012;485(7398):333-8.
    Species: Human
    Sample Type: Plasma
  16. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.
    Authors: Dubois SG, Shusterman S, Ingle AM, Ahern CH, Reid JM, Wu B, Baruchel S, Glade-Bender J, Ivy P, Grier HE, Adamson PC, Blaney SM
    Clin. Cancer Res., 2011;17(15):5113-22.
    Species: Human
    Sample Type: Plasma
  17. In vitro vascular tube formation testing as a tool for treatment individualisation in patients with cervical cancer.
    Authors: Landt S, Heidecke H, Korlach S, Reuter C, Schwidde I, Barinoff J, Thill M, Sehouli J, Kummel S
    Anticancer Res., 2011;31(8):2609-15.
    Species: Human
    Sample Type: Serum
  18. Prognostic significance of angiogenic factors in uterine cervical cancer.
    Authors: Landt S, Wehling M, Heidecke H, Jeschke S, Korlach S, Stoblen F, Schmid P, Blohmer JU, Lichtenegger W, Sehouli J, Kummel S
    Anticancer Res., 2011;31(8):2589-95.
    Species: Human
    Sample Type: Serum
  19. Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer.
    Authors: Rahbari NN, Schmidt T, Falk CS, Hinz U, Herber M, Bork U, Buchler MW, Weitz J, Koch M
    BMC Cancer, 2011;11(0):286.
    Species: Human
    Sample Type: Serum
  20. Effect of smoking on circulating angiogenic factors in high risk pregnancies.
    Authors: Jeyabalan A, Powers RW, Clifton RG, Van Dorsten P, Hauth JC, Klebanoff MA, Lindheimer MD, Sibai B, Landon M, Miodovnik M, Caritis S, Roberts JM, Kuller J, Cotroneo M, Kamon T, Mercer B, Ramsey R, Paul R, Rabello Y, McCart D, Mueller E, Goldenberg R, Copper R, Sorokin Y, Norman G, Millinder A, Christmas JT, McCoy S, Elder S, Elder N, Carter B, Pemberton V, Thurnau G, Meier A, Minton V, Meis P, Swain M, Moawad AH, Jones P, Iams JD, Meadows S, Brenner S, Collins B, Newman RB, Carter SG, Romero R, Sabo V, Thom E, Bain RP, MacPherson C, Johnson D, Fischer ML, McNellis D, Spong C, Catz C, Yaffe S
    PLoS ONE, 2010;5(10):e13270.
    Species: Human
    Sample Type: Serum
  21. Soluble fms-Like tyrosine kinase 1 (sFlt1), endoglin and placental growth factor (PlGF) in preeclampsia among high risk pregnancies.
    Authors: Powers RW, Jeyabalan A, Clifton RG
    PLoS ONE, 2010;5(10):e13263.
    Species: Human
    Sample Type: Serum
  22. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia.
    Authors: Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, Dudenhausen JW, Denk B, Stepan H
    Am. J. Obstet. Gynecol., 2010;202(2):161.e1-161.e1.
    Species: Human
    Sample Type: Serum
  23. Soluble Flt-1 gene therapy ameliorates albuminuria but accelerates tubulointerstitial injury in diabetic mice.
    Authors: Kosugi T, Nakayama T, Li Q, Chiodo VA, Zhang L, Campbell-Thompson M, Grant M, Croker BP, Nakagawa T
    Am. J. Physiol. Renal Physiol., 2010;298(3):F609-16.
    Species: Human
    Sample Type: Urine
  24. Periodic assessment of plasma sFlt-1 and PlGF concentrations and its association with placental morphometry in gestational hypertension (GH) - a prospective follow-up study.
    Authors: Jeevaratnam K, Nadarajah VD, Judson JP
    BMC Pregnancy Childbirth, 2010;10(0):58.
    Species: Human
    Sample Type: Plasma
  25. Signs of reduced angiogenic activity after surgical removal of deeply infiltrating endometriosis.
    Authors: Bourlev V, Iljasova N, Adamyan L, Larsson A, Olovsson M
    Fertil. Steril., 2010;94(1):52-7.
    Species: Human
    Sample Type: Serum
  26. Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice.
    Authors: Sallinen H, Anttila M, Narvainen J, Koponen J, Hamalainen K, Kholova I, Heikura T, Toivanen P, Kosma VM, Heinonen S, Alitalo K, Yla-Herttuala S
    Mol. Ther., 2009;17(2):278-84.
    Species: Human
    Sample Type: Plasma
  27. Are plasma VEGF and its soluble receptor sFlt-1 atherogenic risk factors? Cross-sectional data from the SAPHIR study.
    Authors: Sandhofer A, Tatarczyk T, Kirchmair R, Iglseder B, Paulweber B, Patsch JR, Schratzberger P
    Atherosclerosis, 2009;206(1):265-9.
    Species: Human
    Sample Type: Plasma
  28. Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study.
    Authors: Levine RJ, Vatten LJ, Horowitz GL
    BMJ, 2009;339(0):b4336.
    Species: Human
    Sample Type: Serum
  29. Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease.
    Authors: Findley CM, Mitchell RG, Duscha BD, Annex BH, Kontos CD
    J. Am. Coll. Cardiol., 2008;52(5):387-93.
    Species: Human
    Sample Type: Plasma
  30. Regulation of vascular endothelial growth factor-A and its soluble receptor sFlt-1 by luteinizing hormone in vivo: implication for ovarian follicle angiogenesis.
    Authors: Gutman G, Barak V, Maslovitz S, Amit A, Lessing JB, Geva E
    Fertil. Steril., 2008;89(4):922-6.
    Species: Human
    Sample Type: Serum
  31. Natural selection of FLT1 alleles and their association with malaria resistance in utero.
    Authors: Muehlenbachs A, Fried M, Lachowitzer J, Mutabingwa TK, Duffy PE
    Proc. Natl. Acad. Sci. U.S.A., 2008;105(38):14488-91.
    Species: Human
    Sample Type: Cell Culture Supernates
  32. Cigarette smoke exposure and angiogenic factors in pregnancy and preeclampsia.
    Authors: Jeyabalan A, Powers RW, Durica AR, Harger GF, Roberts JM, Ness RB
    Am. J. Hypertens., 2008;21(8):943-7.
    Species: Human
    Sample Type: Plasma
  33. Angiogenesis markers (VEGF, soluble receptor of VEGF and angiopoietin-1) in very early arthritis and their association with inflammation and joint destruction.
    Authors: Clavel G, Bessis N, Lemeiter D, Fardellone P, Mejjad O, Menard JF, Pouplin S, Boumier P, Vittecoq O, Le Loet X, Boissier MC
    Clin. Immunol., 2007;124(2):158-64.
    Species: Human
    Sample Type: Serum
  34. Significant decrease in angiopoietin-1 and angiopoietin-2 after radical prostatectomy in prostate cancer patients.
    Authors: Caine GJ, Ryan P, Lip GY, Blann AD
    Cancer Lett., 2007;251(2):296-301.
    Species: Human
    Sample Type: Plasma
  35. Changes in plasma vascular endothelial growth factor, angiopoietins, and their receptors following surgery for breast cancer.
    Authors: Caine GJ, Stonelake PS, Lip GY, Blann AD
    Cancer Lett., 2007;248(1):131-6.
    Species: Human
    Sample Type: Plasma
  36. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction.
    Authors: Wallner W, Sengenberger R, Strick R, Strissel PL, Meurer B, Beckmann MW, Schlembach D
    Clin. Sci., 2007;112(1):51-7.
    Species: Human
    Sample Type: Serum
  37. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis.
    Authors: Masuyama H, Suwaki N, Nakatsukasa H, Masumoto A, Tateishi Y, Hiramatrsu Y
    Am. J. Obstet. Gynecol., 2006;194(2):551-6.
    Species: Human
    Sample Type: Serum
  38. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.
    Authors: Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, Epstein FH, Romero R, Thadhani R, Karumanchi SA
    N. Engl. J. Med., 2006;355(10):992-1005.
    Species: Human
    Sample Type: Serum
  39. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.
    Authors: Mross K, Drevs J, Muller M, Medinger M, Marme D, Hennig J, Morgan B, Lebwohl D, Masson E, Ho YY, Gunther C, Laurent D, Unger C
    Eur. J. Cancer, 2005;41(9):1291-9.
    Species: Human
    Sample Type: Serum
  40. Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta.
    Authors: Li H, Gu B, Zhang Y, Lewis DF, Wang Y
    Placenta, 2005;26(2):210-7.
    Species: Human
    Sample Type: Cell Culture Supernates
  41. Urinary placental growth factor and risk of preeclampsia.
    Authors: Levine RJ, Thadhani R, Qian C, Lam C, Lim KH, Yu KF, Blink AL, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA
    JAMA, 2005;293(1):77-85.
    Species: Human
    Sample Type: Urine
  42. Urinary angiogenic factors cluster hypertensive disorders and identify women with severe preeclampsia.
    Authors: Buhimschi CS, Norwitz ER, Funai E, Richman S, Guller S, Lockwood CJ, Buhimschi IA
    Am. J. Obstet. Gynecol., 2005;192(3):734-41.
    Species: Human
    Sample Type: Urine
  43. GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice.
    Authors: Eubank TD, Roberts R, Galloway M, Wang Y, Cohn DE, Marsh CB
    Immunity, 2004;21(6):831-42.
    Species: Human
    Sample Type: Cell Culture Supernates
  44. Circulating angiogenic factors and the risk of preeclampsia.
    Authors: Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA
    N. Engl. J. Med., 2004;350(7):672-83.
    Species: Human
    Sample Type: Serum
  45. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.
    Authors: Maynard SE, Min JY, Merchan J, Lim KH, Mondal S, Stillman IE, Epstein FH, Karumanchi SA
    J. Clin. Invest., 2003;111(5):649-58.
    Species: Human
    Sample Type: Serum
Expand to show all Citations

FAQs

No product specific FAQs exist for this product, however you may

View all ELISA FAQs
ELISA Controls
Description Application Cat# Citations Images  

Have you used Human VEGF R1/Flt-1 Quantikine ELISA Kit?

Submit a review and receive a $25US/€18/£15/$25CAN amazon gift card if you include an image - $10US/€7/£6/$10CAN Amazon card for reviews without an image. Limited to verified customers in USA, Canada and Europe.

Order Details

Contact Information

reload

Feedback

Customer Information

Certificate of Analysis Lookup

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Certificate of Analysis Lookup

Certificate of Analysis Request Form

To download a Certificate of Analysis, please enter the catalog and lot numbers in the search box below.

Note: Certificate of Analysis not available for kit components.

R&D Systems Guarantee

Associated Pathways

Customers Who Viewed
This Item Also Viewed